Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
43.63
-0.53 (-1.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
3 Biotech Stocks With the Strongest Clinical Pipelines
↗
November 08, 2023
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
↗
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
↗
November 06, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Where Exelixis Stands With Analysts
↗
November 02, 2023
Via
Benzinga
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
↗
November 02, 2023
EXEL earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Earnings Outlook For Exelixis
↗
October 31, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
↗
October 18, 2023
There is one key reason to consider the stock.
Via
The Motley Fool
14 Analysts Have This to Say About Exelixis
↗
October 11, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
↗
September 15, 2023
The best may be yet to come for these companies.
Via
The Motley Fool
The Latest Analyst Ratings for Exelixis
↗
September 13, 2023
Via
Benzinga
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
↗
October 28, 2023
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.
Via
The Motley Fool
Topics
Stocks
Why Exelixis Stock Is Trading Lower Today
↗
October 23, 2023
Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
↗
October 19, 2023
These three lesser-known biotech companies are profitable and growing revenue.
Via
The Motley Fool
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
↗
October 13, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
Via
Chartmill
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
↗
October 02, 2023
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
↗
September 29, 2023
Via
Benzinga
Where Exelixis Stands With Analysts
↗
August 22, 2023
Via
Benzinga
Analyst Expectations for Exelixis's Future
↗
August 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023
↗
September 26, 2023
Via
Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
↗
September 20, 2023
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
Via
InvestorPlace
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
↗
September 16, 2023
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...
Via
Talk Markets
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
↗
September 16, 2023
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.
Via
The Motley Fool
Topics
Stocks
The Top Healthcare Stocks to Buy With $100
↗
August 30, 2023
Both stocks have outperformed the broader market in the last 12 months.
Via
The Motley Fool
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
↗
August 24, 2023
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
↗
August 24, 2023
These two companies make a compelling case for a high price.
Via
The Motley Fool
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
↗
August 21, 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time.
Via
InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
↗
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
Exelixis Stock Sees Rising Relative Strength Rating
↗
August 14, 2023
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.
Via
Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
↗
August 08, 2023
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
↗
August 08, 2023
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today